CLINICAL_TRIALS
trial_result
· 2019-10-29
Clinical Trial Update: Pazopanib in Patients With Progressive Recurrent and/or Metastatic Salivary Gland Carcinoma [Phase 2]
Summary
Phase 2 trial evaluating pazopanib in patients with progressive recurrent and/or metastatic salivary gland carcinoma has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: UNICANCER | Conditions: Salivary Gland Carcinoma | Phase 2 | Status: COMPLETED